Search results
Results from the WOW.Com Content Network
The Ludwig Institute for Cancer Research (LICR) maintains the "CTDatabase." [4] This database is an authoritative list of known CT antigens. It also serves as a repository into which new candidates can be entered. Important CT antigens in cancer therapy include MAGE-A1, MAGE-A3, MAGE-A4, NY-ESO-1, PRAME, CT83 and SSX2.
Database Institute / Organization Alteration Types Primary Source [t 1] Processed Data [t 2] Organisms Cell lines [t 3] Public Data [t 4] Restricted Data [t 5]; The BioExpress® Oncology Suite from Ocimum Bio Solutions contains gene expression data from primary, metastatic, and benign tumor samples, and normal samples, including matched adjacent controls.
For cervical carcinoma patients, long antigenic peptides derived from HPV proteins were used in cancer vaccines. It was shown that relative to the corresponding 9 amino acid peptides these peptides of 30-40 amino acids were better incorporated and presented by dendritic cells , leading to improved immunogenicity .
Efficient presentation of antigenic peptides by MHC class I molecules provides the key signal for adaptive immune responses by cytotoxic (CD8 +) T lymphocytes.In the "endogenous" antigen presentation pathway, proteins synthesized by cells undergo cytosolic degradation and some of their peptide fragments are transported to the ER, where suitable-length peptides are loaded onto MHC class I ...
Tumor antigen is an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy. The field of cancer immunology studies such topics.
Neoepitopes are a class of major histocompatibility complex (MHC) bounded peptides. [1] They represent the antigenic determinants of neoantigens. Neoepitopes are recognized by the immune system as targets for T cells and can elicit immune response to cancer. [2] [3]
Thus ERAP2 has been shown to shorten peptides of 9 or fewer amino acids, thereby destroying antigenic peptides in some cases. [5] [6] ERAP2 displays a preference for peptide substrates that carry N-terminal basic residues (arginine, lysine). [7] A fraction of ERAP2 is reported to form complexes with ERAP1, as seen in co-precipitation ...
Tecemotide is a synthetic lipopeptide that is 27 amino acids long. Its molecular formula is C 124 H 203 N 33 O 38, and its amino acid sequence is S T A PPAH G VTSAPDTRPAPGSTAPPKG. The first 25 amino acids of tecemotide are derived from the mucin 1 (MUC1, carcinoma-associated mucin, episialin, or CD227) sequence.